Saturday, August 9, 2014

Non-genotype 1 Infections Comprise over 50 Percent of all HCV Cases

Non-genotype 1 Infections Comprise over 50 Percent of all HCV Cases

Genotypes 4,5 are more prevalent in lower-income countries

Published online July 28 in Hepatology:
Abstract
Full Text

In one of the largest prevalence studies to date, researchers from the United Kingdom provide national, regional, and global genotype prevalence estimates for the hepatitis C virus (HCV). Findings indicate that genotype 1 is the most prevalent worldwide, with over 83 million patients infected of which one-third reside in East Asia. Genotype 3, at just over 54 million cases, is the next most prevalent, followed by genotypes 2, 4, 6, and 5.

Despite efforts to control HCV, it remains one of the most prevalent diseases globally, with up to 150 million patients living with chronic infection according to the World Health Organization (WHO). Previous research shows that chronic HCV leads to the development liver cirrhosis, hepatocellular carcinoma (HCC) or liver cancer, liver failure, and death. WHO reports that 350,000 to 500,000 deaths each year are caused by liver diseases related to HCV.

“While the HCV infection rate is decreasing in developed countries, deaths from liver disease secondary to HCV will continue increasing over the next 20 years,” explains lead co-author Dr. Jane Messina with the University of Oxford in the UK. Understanding the global trends in the genetic makeup of HCV is the focus of our study and is imperative in developing new treatment strategies that may save millions of lives around the world.”

Researchers identified 1,217 medical studies between 1989 (the year HCV was discovered) and 2013 that reported HCV genotypes. The data were then combined with HCV prevalence estimates from the WHO Global Burden of Disease project. Roughly 90 percent of the global population, representing 117 countries, was included in this study.

Analysis shows that HCV genotype 1 is the most prevalent at 46 percent of all HCV cases, followed by genotype 3 at 30 percent; genotypes 2, 4, and 6 with a combined total of 23 percent and genotype 5 at less than 1 percent. Researchers highlight that genotypes 1 and 3 are most dominant regardless of economic status, but found lower-income countries had larger concentrations of genotypes 4 and 5.

Dr. Eleanor Barnes with the University of Oxford adds, "The testing of new therapeutics is still dependent upon knowledge of viral genotype. Non-genotype 1 HCV comprises more than half of all HCV cases. Our study provides evidence of genotype prevalence for specific countries and regions that will help improve access to new viral therapies to combat HCV."

2014 © The American Association for the Study of Liver Diseases

No comments:

Post a Comment